

Histogenics Corporation  
830 Winter Street, 3rd Floor  
Waltham, MA 02451

November 2, 2016

VIA EDGAR

Securities and Exchange Commission  
Division of Corporation Finance  
100 F. Street, N.E.  
Washington, D.C. 20549  
Attention: Amanda Ravitz  
Tim Buchmiller  
Brian Soares

**Re: Histogenics Corporation  
Registration Statement on Form S-3 (File No. 333-213980)  
Request For Acceleration**

Dear Ms. Ravitz and Messrs. Buchmiller and Soares:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Histogenics Corporation (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at 5:00 p.m. Eastern Time on Friday, November 4, 2016 or as soon thereafter as practicable.

The Company hereby authorizes Albert Vanderlaan of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

Please provide a copy of the Commission's order declaring the Registration Statement effective to Albert Vanderlaan at Gunderson Dettmer, One Marina Park Drive, Suite 900, Boston, MA 02210. If possible, please also send such order by email to the attention of Albert Vanderlaan at [avanderlaan@gunder.com](mailto:avanderlaan@gunder.com).

Thank you for your attention on this matter.

Very truly yours,

Histogenics Corporation

By: /s/ Jonathan Lieber

Jonathan Lieber  
Chief Financial Officer

cc: Adam Gridley, Histogenics Corporation  
Marc Dupré, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP  
Keith Scherer, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP